Company profile for Bonus BioGroup

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Bonus BioGroup (TASE: BONS) is a biotechnology company applying a proprietary, innovative technology to generate viable tissue-regenerating bone grafts. The company strives to become a world leader in the field of tissue engineering and live bone transplantation. A unique method for growing a three dimensional (3D) high-density live bone graft – BonoFillTM, was developed by the company. BonoFillTM is derived from the patient...
Bonus BioGroup (TASE: BONS) is a biotechnology company applying a proprietary, innovative technology to generate viable tissue-regenerating bone grafts. The company strives to become a world leader in the field of tissue engineering and live bone transplantation. A unique method for growing a three dimensional (3D) high-density live bone graft – BonoFillTM, was developed by the company. BonoFillTM is derived from the patient's own (autologous) cells. BonoFillTM is constructed of a variety of cells which are grown in multi-layers within a bioreactor system.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Israel
Address
Address
Haifa, Matam Advanced Technology Park
Telephone
Telephone
+972 (0)73 206 7104
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/07/14/3114626/0/en/Bonus-Biogroup-Appoints-Renowned-Cell-Therapy-Leader-Professor-Edwin-M-Horwitz-MD-PhD-to-its-Advisory-Board.html

GLOBENEWSWIRE
14 Jul 2025

https://www.globenewswire.com/news-release/2025/02/20/3029598/0/en/Bonus-Biogroup-Announces-U-S-Food-and-Drug-Administration-FDA-Clearance-of-an-Investigational-New-Drug-IND-Application-for-MesenCure-Phase-III-Clinical-Study-in-Respiratory-Distres.html

GLOBENEWSWIRE
20 Feb 2025

https://www.biospace.com/article/releases/wize-pharma-receives-bonus-biogroup-shares-from-escrow-and-additional-bonus-biogroup-shares-totaling-1-3-million/?s=79

BIOSPACE
04 Jan 2021

https://www.prnewswire.com/il/news-releases/wize-pharmas-strategic-transaction-partner-bonus-biogroup-to-present-mesencure-data-at-the-international-society-for-cell--gene-therapy-isct-annual-meeting-on-may-28-29-2020-301066108.html

PRNEWSWIRE
27 May 2020

https://www.prnewswire.com/news-releases/wize-pharmas-strategic-transaction-partner-bonus-biogroup-reports-successful-treatment-of-acute-pneumonia-in-preclinical-covid-19-model-301060749.html

PRNEWSWIRE
18 May 2020

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty